Edition:
United Kingdom

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

1.86USD
21 Feb 2018
Change (% chg)

$-0.02 (-1.06%)
Prev Close
$1.88
Open
$1.88
Day's High
$1.91
Day's Low
$1.86
Volume
5,131
Avg. Vol
108,519
52-wk High
$3.75
52-wk Low
$0.78

Select another date:

Wed, Jan 17 2018

BRIEF-Aeterna Zentaris Enters Licensing Agreement With Strongbridge For Macrilen In U.S., Canada

* AETERNA ZENTARIS ENTERS INTO LICENSING AND ASSIGNMENT AGREEMENT WITH STRONGBRIDGE FOR MACRILEN™ (MACIMORELIN) IN THE U.S. AND CANADA

BRIEF-Aeterna Zentaris Provides Update On Litigation Against David Dodd And Philip Theodore

* AETERNA ZENTARIS PROVIDES UPDATE ON LITIGATION AGAINST DAVID DODD AND PHILIP THEODORE

BRIEF-David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris

* DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency.

Canada's Aeterna gets FDA approval for growth hormone deficiency test

Dec 20 Canada's Aeterna Zentaris Inc said on Wednesday the U.S. Food and Drug Administration has approved its oral test to diagnose adult growth hormone deficiency. The company said it intends to launch the test, Macrilen, in the United States during the first quarter of 2018.

BRIEF-Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency

* AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY

BRIEF-Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer

* AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER

BRIEF-Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA

* AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY

BRIEF-Aeterna Zentaris reports Q3 loss per share of $0.61

* Aeterna Zentaris reports third quarter 2017 financial and operating results

BRIEF-Aeterna Zentaris announces appointment of interim chief financial officer

* Aeterna zentaris announces appointment of interim chief financial officer

Select another date: